Medtronic plc

NYSE:MDT

Medical - Devices

Healthcare
$100.72 +0.96%

+$0.75 today

Market cap
$128.84B
Beta
0.60
P/E (TTM)
21.1
EPS (TTM)
$3.74
Dividend yield
3.60%
52W Low $73.31High $106.33

Volume 6.47M

Average 11.36M

MDT Other Financing Activities

Financing cash flows not reported separately.

Medtronic plcNYSE: MDT

Other Financing Activities · Q1 FY2027 · quarter ended Jul 2026

Other financing activities dips below year-ago levels

Q1 FY2027 other financing activities of $13M fell 81.4% year over year, behind the +630.3% change in trailing-twelve-month other financing activities. Sequentially, it fell 97.5% from the prior quarter.

Context

  • Other financing activities amounted to 1.6% of revenue in FY2026, up 1.1 pp from a year earlier.
  • Other financing activities increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -81.4% toward the trailing-twelve-month pace of +630.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
$13M-97.5% QoQ
Last fiscal yearApr 2026
$582M+416.3% YoY
LTMJul 2026
$525M+630.3% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.4%——
1 year+416.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2026
582M USD
Year-over-year change
+416.3%
4-year CAGR
+37.5%

Other Financing Activities vs competitors

How MDT compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +630.3% is the 5th highest of 9, against a peer median of +756.1%.
  • Other financing activities amounts to 1.4% of revenue for MDT, versus a peer median of 3.0%.
MDT Competitors
Other Financing Activities for MDT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EWEdwards Lifesciences CorporationLTM Jun 2026$899.3M USD+621.7%—13.8%
SYKStryker CorporationLTM Jun 2026$602M USD+1924.2%-11.7%2.3%
MDTMedtronic plcLTM Jul 2026$525M USD+630.3%—1.4%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$314M USD+890.5%—3.7%
BSXBoston Scientific CorporationLTM Jun 2026$158M USD-43.2%-26.3%0.8%
LIVNLivaNova PLCLTM Sep 2026$55.62M USD+5074.1%—3.7%
PHGKoninklijke Philips N.V.LTM Jun 2026€36.71M EUR+3388.3%+27.3%0.2%
PENPenumbra, Inc.LTM Jun 2026$2.07M USD+21.1%-30.0%0.1%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.17M USD-47.0%+5.4%63.0%
Peer median (excluding MDT) —+756.1%-11.7%3.0%

Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Apr 2026
Net Income5.06B3.78B3.68B4.69B4.84B
Depreciation & Amortization2.71B2.7B2.65B2.86B2.96B
Deferred Income Tax(604M)(226M)(508M)(316M)51M
Stock-Based Compensation359M355M393M429M457M
Change in Working Capital(889M)(967M)(484M)(1.05B)(1.42B)
Accounts Receivables(477M)(576M)(391M)(433M)(200M)
Inventory(560M)(939M)(139M)(292M)(404M)
Accounts Payables213M696M391M209M46M
Other Working Capital(65M)(148M)(345M)(538M)(865M)
Other Non-Cash Items711M396M1.06B433M450M
Operating Cash Flow7.35B6.04B6.79B7.04B7.33B
Capital Expenditures(1.37B)(1.46B)(1.59B)(1.86B)(1.9B)
Acquisitions (Net)(91M)(1.87B)(211M)(98M)(406M)
Purchases of Investments(9.88B)(7.51B)(7.75B)(8.23B)(8.73B)
Sales of Investments9.69B7.34B7.44B8.5B8.11B
Other Investing Activities(10M)4M(261M)(249M)(4M)
Investing Cash Flow(1.66B)(3.49B)(2.37B)(1.94B)(2.93B)
Debt Repayment(1M)(598M)1.07B2.14B(1.17B)
Common Stock Issued429M308M284M508M516M
Common Stock Repurchased(2.54B)(645M)(2.14B)(3.24B)(1.04B)
Dividends Paid(3.38B)(3.62B)(3.67B)(3.59B)(3.64B)
Other Financing Activities163M(101M)(3M)(184M)582M
Financing Cash Flow(5.34B)(4.96B)(4.45B)(4.36B)(4.75B)
Effect of Forex Changes(230M)243M(230M)188M85M
Net Change in Cash121M(2.17B)(259M)934M(269M)
Free Cash Flow5.98B4.58B5.2B5.19B5.43B

Medtronic plc

NYSE:MDT

Intrinsic Alpha fair value

Locked

Current Price

$100.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.